Abstract:
The transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel with high calcium permeability that has been studied extensively since its identification and characterization in 1997. Its involvement in different modalities of pain has been well documented, which has resulted in the development of novel strategies for the treatment of pain. However, TRPV1 is also involved in a plethora of other physiological and pathophysiological functions related to urinary, cardiovascular, gastrointestinal, respiratory, and central nervous systems. Here, we summarize the recent developments of the role of TRPV1 in acquired diseases and review the current perspective of TRPV1 agonist and antagonist as potential drugs for therapeutic intervention.